NEW YORK (GenomeWeb) – Edico Genome said today that it raised $10 million in a Series A round of financing that it will use to commercialize its Dragen Bio-IT Processor, an application-specific integrated circuit system for next-generation sequence data analysis.

The financing round was led by Qualcomm through its venture investment group Qualcomm Ventures. The list of investors includes Axon Ventures and Greg Lucier, former Life Technologies chairman and CEO. As part of his investment, Lucier has joined Edico Genome's board of directors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.